- Home
- MYNZ vs OGEN Comparison
MYNZ vs OGEN Comparison
Compare MYNZ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- OGEN
- Stock Information
- Founded
- MYNZ 2021
- OGEN 1996
- Country
- MYNZ Germany
- OGEN United States
- Employees
- MYNZ N/A
- OGEN N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- OGEN Health Care
- Exchange
- MYNZ Nasdaq
- OGEN Nasdaq
- Market Cap
- MYNZ 5.5M
- OGEN 2.5M
- IPO Year
- MYNZ 2021
- OGEN N/A
- Fundamental
- Price
- MYNZ $1.40
- OGEN $3.83
- Analyst Decision
- MYNZ Buy
- OGEN
- Analyst Count
- MYNZ 2
- OGEN 0
- Target Price
- MYNZ $14.00
- OGEN N/A
- AVG Volume (30 Days)
- MYNZ 120.1K
- OGEN 655.3K
- Earning Date
- MYNZ 07-07-2025
- OGEN 08-08-2025
- Dividend Yield
- MYNZ N/A
- OGEN N/A
- EPS Growth
- MYNZ N/A
- OGEN N/A
- EPS
- MYNZ N/A
- OGEN N/A
- Revenue
- MYNZ $893,991.00
- OGEN N/A
- Revenue This Year
- MYNZ $26.06
- OGEN N/A
- Revenue Next Year
- MYNZ $4.97
- OGEN N/A
- P/E Ratio
- MYNZ N/A
- OGEN N/A
- Revenue Growth
- MYNZ N/A
- OGEN N/A
- 52 Week Low
- MYNZ $1.34
- OGEN $3.12
- 52 Week High
- MYNZ $22.40
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- MYNZ 23.25
- OGEN 47.04
- Support Level
- MYNZ $1.34
- OGEN $3.41
- Resistance Level
- MYNZ $1.48
- OGEN $4.85
- Average True Range (ATR)
- MYNZ 0.13
- OGEN 0.58
- MACD
- MYNZ -0.01
- OGEN 0.01
- Stochastic Oscillator
- MYNZ 3.72
- OGEN 42.49
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.